PL356105A1 - Analogi kwasu hydroksyeikozatetraenowego oraz sposoby ich zastosowania do leczenia zespołu suchego oka - Google Patents

Analogi kwasu hydroksyeikozatetraenowego oraz sposoby ich zastosowania do leczenia zespołu suchego oka

Info

Publication number
PL356105A1
PL356105A1 PL00356105A PL35610500A PL356105A1 PL 356105 A1 PL356105 A1 PL 356105A1 PL 00356105 A PL00356105 A PL 00356105A PL 35610500 A PL35610500 A PL 35610500A PL 356105 A1 PL356105 A1 PL 356105A1
Authority
PL
Poland
Prior art keywords
methods
dry eye
acid analogs
eye disorders
treating dry
Prior art date
Application number
PL00356105A
Other languages
English (en)
Other versions
PL202040B1 (pl
Inventor
Peter G. Klimko
Mark R. Hellberg
John R. Falck
Raymond E. Conrow
Original Assignee
Alcon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc. filed Critical Alcon Inc.
Publication of PL356105A1 publication Critical patent/PL356105A1/pl
Publication of PL202040B1 publication Critical patent/PL202040B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL356105A 1999-11-09 2000-10-23 Analogi kwasu hydroksyeikozatetraenowego, ich zastosowanie i zawierająca je kompozycja do leczenia zespołu suchego oka PL202040B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16437199P 1999-11-09 1999-11-09
US16436999P 1999-11-09 1999-11-09
US16438699P 1999-11-09 1999-11-09
PCT/US2000/029243 WO2001034551A1 (en) 1999-11-09 2000-10-23 Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders

Publications (2)

Publication Number Publication Date
PL356105A1 true PL356105A1 (pl) 2004-06-14
PL202040B1 PL202040B1 (pl) 2009-05-29

Family

ID=27389011

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356105A PL202040B1 (pl) 1999-11-09 2000-10-23 Analogi kwasu hydroksyeikozatetraenowego, ich zastosowanie i zawierająca je kompozycja do leczenia zespołu suchego oka

Country Status (18)

Country Link
EP (1) EP1228029B1 (pl)
JP (1) JP4663193B2 (pl)
KR (1) KR100781354B1 (pl)
CN (1) CN1390191A (pl)
AR (1) AR029769A1 (pl)
AT (2) ATE287866T1 (pl)
AU (1) AU776254B2 (pl)
BR (1) BR0015424A (pl)
CA (1) CA2386627C (pl)
DE (2) DE60012358T2 (pl)
DK (1) DK1228029T3 (pl)
ES (2) ES2233921T3 (pl)
HK (1) HK1045983B (pl)
MX (1) MXPA02004704A (pl)
PL (1) PL202040B1 (pl)
PT (2) PT1228029E (pl)
TW (1) TWI281395B (pl)
WO (1) WO2001034551A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
CA2643972C (en) * 2006-04-19 2012-01-03 Peter Demin Hepoxilin analog enantiomers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906467A (en) 1988-03-24 1990-03-06 New York Medical College Novel, long-duration treatment for glaucoma
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders

Also Published As

Publication number Publication date
CN1390191A (zh) 2003-01-08
DE60017810D1 (de) 2005-03-03
PL202040B1 (pl) 2009-05-29
WO2001034551A1 (en) 2001-05-17
EP1228029B1 (en) 2004-07-21
JP2003528042A (ja) 2003-09-24
MXPA02004704A (es) 2004-09-10
PT1228029E (pt) 2004-10-29
CA2386627A1 (en) 2001-05-17
ATE271534T1 (de) 2004-08-15
DE60012358D1 (de) 2004-08-26
HK1045983A1 (en) 2002-12-20
AU776254B2 (en) 2004-09-02
KR100781354B1 (ko) 2007-11-30
ES2233921T3 (es) 2005-06-16
BR0015424A (pt) 2002-07-16
ATE287866T1 (de) 2005-02-15
HK1045983B (en) 2004-12-24
EP1228029A1 (en) 2002-08-07
DE60017810T2 (de) 2005-08-25
PT1418167E (pt) 2005-05-31
AR029769A1 (es) 2003-07-16
HK1063623A1 (en) 2005-01-07
DE60012358T2 (de) 2005-02-17
KR20020040849A (ko) 2002-05-30
JP4663193B2 (ja) 2011-03-30
DK1228029T3 (da) 2004-10-25
CA2386627C (en) 2008-12-23
ES2220559T3 (es) 2004-12-16
AU1226201A (en) 2001-06-06
TWI281395B (en) 2007-05-21

Similar Documents

Publication Publication Date Title
PL355998A1 (pl) Kompozycje zawierające pochodne kwasu hydroksyeikozatetraenowego oraz sposoby ich zastosowania w leczeniu zespołu suchego oka
HRP20000201B1 (en) Prostaglandin agonists and their use to treat bone disorders
PL356093A1 (pl) Hydroksyeikozatetraeniany, sole, kompozycje i sposoby ich zastosowania w leczeniu zespołu suchego oka
HUP0003298A3 (en) Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
HUP0102781A3 (en) Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies
PL349193A1 (en) Branched chain amino acid−dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
NO20030295D0 (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
PL364171A1 (pl) Kryształy pochodnej kwasu oksyiminoalkanoesowego i ich zastosowanie jako leków przeciwcukrzycowych
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
NO990019L (no) Anvendelse av T-BAM (CD40L) ved behandling av sykdommer i glatt muskulatur
PL356105A1 (pl) Analogi kwasu hydroksyeikozatetraenowego oraz sposoby ich zastosowania do leczenia zespołu suchego oka
AU8031400A (en) 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
PL356127A1 (pl) Pochodne kwasu 15-hydroksyeikozatetraenowego ze zmodyfikowanym łańcuchem omega oraz sposoby ich zastosowania do leczenia zespołu suchego oka
EP1150669A4 (en) FORMULATIONS ON L-ARGININE BASE FOR DISEASE TREATMENT AND USE THEREOF
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
IL127464A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
HUP0102776A3 (en) Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
GB0229366D0 (en) Improvements in and relating to methods and apparatus for the application of honey to wounds
EP1418167A3 (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
EP1096948A4 (en) USE OF INTERLEUKIN-11 FOR TREATING GASTROINTESTINAL DISEASES
EP0456204A3 (en) Use of benzocycloheptathiophenecarboxylic acid derivatives in the treatment of eosinophile accumulation/activation and connected diseases
IT1284530B1 (it) Impiego dell&#39;acido 5-meti-tetraidrofolico nella terapia e nella prevenzione dei danni vascolari e trombotici in soggetti
GB9828845D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases